MedicalResearch.com Interview with:
Dr. Audrey Coilly MD
Fellow at the Centre Hepato-Biliaire
Paul Brousse Hospital
Medical Research: What is the background for this study? What are the main findings?
Dr. Coilly: Hepatitis C (HCV) recurrence used to be a major issue during two decades for patients transplanted with an active HCV infection at the time of transplantation impacting both patient and graft survival. The combination of sofosbuvir and daclatasvir has not been studied after liver transplantation. The main findings are a high efficacy profile with an overall SVR12 rate of 95%. The safety profile is also good. The most frequent adverse event is anemia, particularly when ribavirin is still used.
Medical Research: What should clinicians and patients take away from your report?
Dr. Coilly: This combination is a good option to treat HCV recurrence. The use of ribavirin does not seem to be mandatory but the enrollment of more severe patients in the RBV group justify to be very cautious regarding RBV avoidance and treatment duration. A decrease in creatinine clearance has been observed during treatment without clear explanation. Physicians should monitor carefully renal impairment during treatment.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Coilly: We recommend to precisely look what happens in term of drug-drug interactions.
THE ASSOCIATION OF SOFOSBUVIR AND DACLATASVIR FOR TREATING SEVERE RECURRENCE OF HCV INFECTION AFTER LIVER TRANSPLANTATION: RESULTS FROM A LARGE FRENCH PROSPECTIVE MULTICENTRIC ANRS CO23 CUPILT COHORT
MedicalResearch.com Interview with: Dr. Audrey Coilly MD (2015). Combination Medication Effective Hepatitis C Recurrence After Liver Transplantation